Investment Rating - The report gives a "Buy" rating for the company, indicating an expected relative increase in stock price of over 20% compared to the benchmark index within six months [9][15]. Core Insights - The company has shown significant improvement in profitability and cost control, indicating a path towards high-quality development. In 2024, the operating revenue was 3.825 billion yuan, a decrease of 10.26%, while the net profit attributable to shareholders was 34 million yuan, an increase of 108.11% [3][4]. - The company has optimized its sales model through a direct sales reform pilot in nine provinces, which has led to steady growth in sales profits in those regions. By the end of 2024, the reform had been completed in six provinces, contributing positively to sales efficiency and profitability [5]. - The research pipeline is robust, with several new drug projects underway, including the Huanglian Jiedu Wan and Tang Ning Tong Luo projects. Successful approval and market entry of these projects could enhance the company's product structure and competitive edge [6]. Financial Performance Summary - For 2024, the gross margin was 58.09%, an increase of 2.80 percentage points, while the net profit margin was 0.88%, up by 10.60 percentage points. However, in Q1 2025, the gross margin dropped to 51.05%, a decrease of 12.79 percentage points [4]. - The company is projected to have revenues of 3.517 billion yuan in 2025, with net profits of 113 million yuan, reflecting a significant growth trajectory in subsequent years [9][11]. - The expected price-to-earnings (P/E) ratios for 2025, 2026, and 2027 are 66.5, 57.8, and 49.5 respectively, indicating a potential for valuation improvement as earnings grow [9][11].